Allogene Therapeutics, Inc. (ALLO) financial statements (2021 and earlier)

Company profile

Business Address 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,000589721
Cash and cash equivalents18317592
Short-term investments645355367
Other undisclosed cash, cash equivalents, and short-term investments17258262
Prepaid expense 53
Other undisclosed current assets(155)(50)(257)
Total current assets:845545468
Noncurrent Assets
Operating lease, right-of-use asset41 
Property, plant and equipment119569
Long-term investments and receivables20863262
Long-term investments20863262
Intangible assets, net (including goodwill) 01
Intangible assets, net (excluding goodwill) 01
Restricted cash and investments941
Other noncurrent assets550
Other undisclosed noncurrent assets 4433
Total noncurrent assets:383173306
TOTAL ASSETS:1,228718774
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10912
Accounts payable10912
Deferred revenue39 
Deferred compensation liability335
Other liabilities531
Other undisclosed current liabilities371812
Total current liabilities:943329
Noncurrent Liabilities
Long-term debt and lease obligation51  
Operating lease, liability51 
Liabilities, other than long-term debt3414
Deferred compensation liability, classified  7
Other liabilities347
Other undisclosed noncurrent liabilities 5128
Total noncurrent liabilities:545641
Total liabilities:1488971
Stockholders' equity
Stockholders' equity attributable to parent1,080629703
Common stock000
Additional paid in capital1,7261,024914
Accumulated other comprehensive income010
Accumulated deficit(646)(396)(212)
Total stockholders' equity:1,080629703
TOTAL LIABILITIES AND EQUITY:1,228718774

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Operating expenses(258)(202)(193)
Operating loss:(258)(202)(193)
Nonoperating income (expense)817(19)
Other nonoperating income9176
Interest and debt expense  (3)
Loss from continuing operations before equity method investments, income taxes:(250)(185)(215)
Other undisclosed income from continuing operations before income taxes  3
Loss from continuing operations before income taxes:(250)(185)(212)
Income tax benefit 00
Net loss available to common stockholders, diluted:(250)(185)(212)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(250)(185)(212)
Other comprehensive loss (0)(0)
Comprehensive loss:(250)(185)(212)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)10
Comprehensive loss, net of tax, attributable to parent:(251)(184)(211)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: